STOK:NASDAQ, Stoke Therapeutics, Inc.
STOK stock overview
Stoke Therapeutics, Inc. (STOK:NASDAQ) closed at $26.61 on October 20, 2026,
up 7.21% on the day.
The stock trades 33.8% below its 52-week high of $40.22
and 31.0% above its 52-week low of $20.32.
Over the past year, it lost 18.2%.
Stoke Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $26.61
- Day change
- +7.21%
- Volume
- 1,996,804
- Average volume
- 908,246
- Market cap
- 1B+
- 52-week range
- $20.32 – $40.22
- 50-day average
- $28.43
- 200-day average
- $31.18
Price action over the past year
In 252 trading sessions since October 20, 2025, STOK closed higher on 121 days (48%).
Its best day was November 11, 2025 (+12.25%) and its worst was November 3, 2025 (-13.12%).
The stock moved 10% or more in a single session 6 times.
Recent signals
STOK news
-
Oct 16, 2026:
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Oct 12, 2026:
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
-
Oct 9, 2026:
FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)
-
Oct 6, 2026:
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
-
Oct 5, 2026:
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
-
Sep 23, 2026:
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
-
Sep 3, 2026:
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
-
Sep 2, 2026:
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
About Stoke Therapeutics, Inc.
Stoke Therapeutics Inc is engaged in developing antisense oligonucleotide medicines. The medicine increases gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney.
Similar stocks
Find more stocks like STOK with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.